TY  - JOUR
AU  - Bischof, Gérard N.
AU  - Brendel, Matthias
AU  - Barthel, Henryk
AU  - Theis, Hendrik
AU  - Barbe, Michael
AU  - Bartenstein, Peter
AU  - Claasen, Joseph
AU  - Danek, Adrian
AU  - Höglinger, Günter
AU  - Levin, Johannes
AU  - Marek, Ken
AU  - Neumaier, Bernd
AU  - Palleis, Carla
AU  - Patt, Marianne
AU  - Rullmann, Michael
AU  - Saur, Dorothee
AU  - Schroeter, Matthias L.
AU  - Seibyl, John
AU  - Song, Mengmeng
AU  - Stephens, Andrew
AU  - Sabri, Osama
AU  - Drzezga, Alexander
AU  - van Eimeren, Thilo
TI  - Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620
JO  - Journal of nuclear medicine
VL  - 65
IS  - 6
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - FZJ-2024-05291
SP  - 952 - 955
PY  - 2024
AB  - We used a new data-driven methodology to identify a set of reference regions that enhanced the quantification of the SUV ratio of the second-generation tau tracer 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c′]dipyridine ([18F]PI-2620) in a group of patients clinically diagnosed with 4-repeat tauopathy, specifically progressive supranuclear palsy or cortical basal syndrome. The study found that SUV ratios calculated using the identified reference regions (i.e., fusiform gyrus and crus-cerebellum) were significantly associated with symptom severity and disease duration. This establishes, for the first time to our knowledge, the suitability of [18F]PI-2620 for tracking disease progression in this 4-repeat disease population. This is an important step toward increased clinical utility, such as patient stratification and monitoring in disease-modifying treatment trials. Additionally, the applied methodology successfully optimized reference regions for automated detection of brain imaging tracers. This approach may also hold value for other brain imaging tracers.
LB  - PUB:(DE-HGF)16
C6  - 38575191
UR  - <Go to ISI:>//WOS:001251294600021
DO  - DOI:10.2967/jnumed.123.265930
UR  - https://juser.fz-juelich.de/record/1030418
ER  -